Vice President Corporate Communications - Corporate Communications
About the job
- 15+ years of progressive communications leadership experience within biotechnology, pharmaceutical, or life sciences organizations, including significant experience leading corporate communications and product or pipeline communications functions.
- Demonstrated success developing and executing communications strategies that support corporate reputation, pipeline advancement, regulatory milestones, commercial readiness, and business objectives.
- Experience serving as a trusted advisor to CEOs, executive teams, and senior leaders in high-growth or high-stakes biotechnology environments.
- Experience working in a publicly traded or investor-facing life sciences company.
- Deep understanding of the biotechnology industry, drug development process, regulatory environment, healthcare stakeholder landscape, and communications considerations associated with potential product approval and launch.
- Demonstrated success operating in a senior individual contributor capacity, balancing strategic leadership with hands-on execution while partnering effectively with agencies and cross-functional teams.
- Proven experience managing high-profile communications initiatives, issues-management situations, crisis preparedness, and corporate reputation challenges.
- Strong media relations experience with established relationships across healthcare, biotechnology, business, and financial media.
- Exceptional written, verbal, and presentation skills, with the ability to translate complex scientific, regulatory, commercial, and business information into clear and compelling narratives.
- Strong executive presence, sound business judgment, strategic thinking, and the ability to influence senior leadership and cross-functional teams.
- Ability to thrive in a fast-paced, high-growth, matrixed biotechnology environment while balancing strategic leadership with operational excellence and hands-on execution.
- Availability to attend in person at the Philadelphia-area office based on business needs and work requirements.
- Willingness to travel based on business needs, including attendance at internal meetings and key company or industry events.
- Develop and lead an integrated communications strategy encompassing corporate communications, product and pipeline communications, executive communications, internal communications, digital communications, media relations, and reputation management.
- Partner with the senior leadership team to define, strengthen, and consistently articulate the company’s corporate narrative across external and internal stakeholder audiences.
- Serve as a trusted strategic communications advisor to the Chief Executive Officer, Chief Commercial Officer, Chief Financial Officer, Chief People Officer, executive leaders, and other senior leaders on positioning, messaging, thought leadership, media engagement, employee communications, and reputation management.
- Lead communications planning and execution for major corporate milestones, including clinical data presentations, regulatory events, potential approval and launch-readiness milestones, scientific congresses, financing activities, business development activities, and other significant corporate announcements.
- Develop and execute product and pipeline communications strategies that support late-stage development, regulatory readiness, and future commercial objectives.
- Build and protect the company’s reputation through proactive issues preparedness, crisis communications planning, and rapid-response communications.
- Oversee media relations strategy, cultivate relationships with healthcare, biotechnology, business, and financial media, and position the company as a credible voice within cardiovascular and other therapeutic-area communities.
- Lead executive communications programs, including keynote presentations, external speaking engagements, thought leadership initiatives, internal leadership messaging, and strategic presentations.
- Partner with the Chief People Officer to lead internal communications strategies that strengthen employee engagement, reinforce culture, and align employees around corporate priorities, business growth, and commercialization milestones.
- Oversee the company’s digital communications ecosystem, including the corporate website, social media channels, and emerging communications platforms.
- Establish communications objectives, metrics, and analytics to assess impact, monitor stakeholder engagement, and continuously improve performance.
- Lead and provide strategic oversight to external communications agencies, public relations partners, creative partners, and consultants.
- Serve as a hands-on leader in an individual contributor capacity, leveraging agency partnerships and cross-functional resources to execute communications strategies while building a scalable communications capability for the future.
- Partner with Legal, Regulatory, Clinical Development, Medical Affairs, Commercial, and Investor Relations teams to develop, refine, and execute accurate, compliant, coordinated, and strategically effective communications strategies, messaging, and content.
About the company
NewAmsterdam Pharma develops oral therapies for cardiometabolic diseases and runs late-stage clinical programs around obicetrapib, a CETP inhibitor aimed at lowering LDL-cholesterol in high-risk cardiovascular disease patients. Its pipeline includes a fixed-dose combo of obicetrapib and ezetimibe in Phase 2 (ROSE2) and three Phase 3 trials (BROADWAY, BROOKLYN, and PREVAIL) to evaluate obicetrapib in HeFH, ASCVD, and as a cardiovascular outcomes trial. Founded in 2019 and based in Naarden, the Netherlands, the company focuses on transforming lipid management and cardiovascular risk reduction through targeted CETP inhibition.
Company Size
51-200
Company Stage
IPO
Headquarters
Naarden, Netherlands
Founded
2019
Get referred to NewAmsterdam Pharma
See people who can refer or advise you
Simplify's Take
What believers are saying
- EMA, UK, and Swiss decisions expected in 2H2026 can unlock Germany and UK launches.
- June 2026 cash of $678.3 million funds PREVAIL, RUBENS, and commercialization through 2027.
- BROADWAY and BROOKLYN showed LDL-C lowering with placebo-like tolerability, supporting physician adoption.
What critics are saying
- PREVAIL interim data in 1Q2027 decides the entire platform; failure crushes NewAmsterdam.
- Merck's July 2026 oral PCSK9 approval steals cardiology mindshare before Menarini launches.
- COO Douglas Kling resigned effective August 14, 2026, signaling execution strain before launches.
What makes NewAmsterdam Pharma unique
- Obicetrapib is the only late-stage oral CETP inhibitor; Europe approved it in July 2026.
- NewAmsterdam pairs monotherapy and ezetimibe FDC across HeFH, ASCVD, and PREVAIL programs.
- Menarini commercialization in Europe gives NewAmsterdam royalties and milestones without building a salesforce.
Help us improve and share your feedback! Did you find this helpful?
Benefits
Health Insurance
Dental Insurance
Vision Insurance
Life Insurance
Disability Insurance
Remote Work Options
Growth & Insights and Company News
6 month growth
0%1 year growth
-1%2 year growth
0%The European Commission has granted marketing authorisation for Ubeslo (obicetrapib monotherapy) and Evlarco (obicetrapib plus ezetimibe fixed-dose combination), marking the first global regulatory approval of obicetrapib. The approval, announced by NewAmsterdam Pharma and Menarini Group, covers treatment for patients with primary hypercholesterolaemia and mixed dyslipidaemia. The authorisation is supported by Phase 3 clinical trials demonstrating LDL cholesterol reductions of up to 40% with obicetrapib monotherapy and approximately 50% when combined with ezetimibe. The treatments showed a tolerability profile comparable to placebo. Menarini holds exclusive commercialisation rights in Europe. NewAmsterdam is entitled to tiered double-digit percentage royalties on net sales and up to €833 million in potential milestone payments. The companies continue advancing obicetrapib's clinical development through multiple ongoing Phase 3 trials, including the PREVAIL cardiovascular outcomes study.
NewAmsterdam Pharma to participate at upcoming investor conferences in September. NAARDEN, The Netherlands and MIAMI, Sept. 02, 2026 (GLOBE NEWSWIRE) - NewAmsterdam Pharma Company N.V. (Nasdaq: NAMS or "NewAmsterdam" or the "Company"), a late-stage, clinical biopharmaceutical company developing oral, non-statin medicines for patients at risk of cardiovascular disease ("CVD") with elevated low-density lipoprotein cholesterol ("LDL-C"), for whom existing therapies are not sufficiently effective or well-tolerated, today announced that company management will participate in the following upcoming investor conferences: * Wells Fargo 21st Annual Healthcare Conference in Boston, MA on Wednesday, September 9, 2026. Michael Davidson, M.D., Chief Executive Officer, and Matthew Philippe, Executive Vice President, Head of Investor Relations, will participate in a fireside chat at 3:45 p.m. ET on Wednesday, September 9. * Cantor Global Healthcare Conference 2026 in New York, NY on Thursday, September 10, 2026. Ian Somaiya, Chief Financial Officer, and Matthew Philippe, Executive Vice President, Head of Investor Relations, will participate in a fireside chat at 2:45 p.m. ET on Thursday, September 10. Live webcasts of both presentations will be available through the investor relations section of the NewAmsterdam Pharma website at ir.newamsterdampharma.com. Following the live webcasts, archived replays will be available on the Company's website. About NewAmsterdam NewAmsterdam Pharma (Nasdaq: NAMS) is a late-stage biopharmaceutical company whose mission is to improve patient care in populations with metabolic diseases where currently approved therapies have not been adequate or well tolerated. We seek to fill a significant unmet need for a safe, well-tolerated and convenient LDL-lowering therapy. In multiple phase 3 trials, NewAmsterdam is investigating obicetrapib, an oral, low-dose and once-daily CETP inhibitor, alone or as a fixed-dose combination with ezetimibe, as LDL-C lowering therapies to be used as an adjunct to statin therapy for patients at risk of CVD with elevated LDL-C, for whom existing therapies are not sufficiently effective or well tolerated. Company Contact Media Contact Real Chemistry on behalf of NewAmsterdam Christian Edgington P: 1-513-310-6410 [email protected] Investor Contact Precision AQ on behalf of NewAmsterdam Austin Murtagh P: 1-212-698-8696 [email protected]
NewAmsterdam Pharma announces upcoming presentations at the European Society of Cardiology (ESC) Congress 2026. NAARDEN, The Netherlands and MIAMI, Aug. 26, 2026 (GLOBE NEWSWIRE) - NewAmsterdam Pharma Company N.V. (Nasdaq: NAMS or "NewAmsterdam" or the "Company"), a late-stage, clinical biopharmaceutical company developing oral, non-statin medicines for patients at risk of cardiovascular disease ("CVD") with elevated low-density lipoprotein cholesterol ("LDL-C"), for whom existing therapies are not sufficiently effective or well-tolerated, today announced that it will present data from its obicetrapib development program at the European Society of Cardiology (ESC) Congress 2026, taking place August 28 - 31, 2026 in Munich, Germany. Presentation details are as follows: Title: Determinants of Short Term Lp(a) Variability in Phase 3 Obicetrapib Trials Session Title: Novel Lipid Lowering Therapies for Residual Risk Session Number: 3579 Moderated Poster Presentation Date and Time: Friday, August 28, 2026 at 10:15-11:00 CET Location: Station 2, Research Gallery Hall A1 Presenters: John Kastelein, M.D., Ph.D., FESC, Chief Scientific Officer, NewAmsterdam Pharma Title: Pooled On-Treatment Lipid-Lowering Efficacy of the CETP Inhibitor Obicetrapib in Phase III Trials Session Title: Lipid Lowering and Cardiovascular Outcomes Session Number: 3582 Moderated Poster Presentation Date and Time: Sunday, August 30, 2026 at 10:15-11:00 CET Location: Station 2, Research Gallery Hall A1 Presenter: Mathijs A.C. de Kleer Title: Extreme HDL-C Associated Increased Mortality is Explained by Confounding Due to Progressively Increasing Alcohol-Induced Multisystem Morbidity Session Title: Lipids and Myocardial Infarction Session Number: 3102 Oral Presentation Date and Time: Monday, August 31, 2026 at 12:30-12:40 CET Location: Science Box 5, Research Gateway Hall A1 Presenter: Brian A. Ference, M.D., MPhil, FACC, FESC About Obicetrapib Obicetrapib is a novel, oral, low-dose CETP inhibitor that NewAmsterdam is developing to overcome the limitations of current LDL-lowering treatments. In each of the Company's Phase 2 trials, ROSE2, TULIP, ROSE, and OCEAN, as well as the Company's Phase 3 BROOKLYN, BROADWAY and TANDEM trials, evaluating obicetrapib as monotherapy or combination therapy, the Company observed statistically significant LDL-lowering combined with a side effect profile similar to that of placebo. The Company commenced the Phase 3 PREVAIL cardiovascular outcomes trial in March 2022, which is designed to assess the potential of obicetrapib to reduce occurrences of MACE. The Company completed enrollment of PREVAIL in April 2024 and randomized over 9,500 patients. Commercialization rights of obicetrapib in Europe, either as a monotherapy or as part of a fixed-dose combination with ezetimibe, have been exclusively granted to the Menarini Group, an Italy-based, leading international pharmaceutical and diagnostics company. About NewAmsterdam NewAmsterdam Pharma (Nasdaq: NAMS) is a late-stage biopharmaceutical company whose mission is to improve patient care in populations with metabolic diseases where currently approved therapies have not been adequate or well tolerated. NewAmsterdam Pharma Company seek to fill a significant unmet need for a safe, well-tolerated and convenient LDL-lowering therapy. In multiple phase 3 trials, NewAmsterdam is investigating obicetrapib, an oral, low-dose and once-daily CETP inhibitor, alone or as a fixed-dose combination with ezetimibe, as LDL-C lowering therapies to be used as an adjunct to statin therapy for patients at risk of CVD with elevated LDL-C, for whom existing therapies are not sufficiently effective or well tolerated. Company Contact Media Contact Real Chemistry on behalf of NewAmsterdam Christian Edgington P: 1-513-310-6410 [email protected] Investor Contact Precision AQ on behalf of NewAmsterdam Austin Murtagh P: 1-212-698-8696 [email protected]
NewAmsterdam Pharma reported second quarter 2026 financial results and announced positive regulatory progress for obicetrapib, its cholesterol-lowering drug candidate. The European Medicines Agency's CHMP has recommended marketing authorisation for obicetrapib as both a monotherapy and in combination with ezetimibe for treating hypercholesterolemia and mixed dyslipidemia. A final European Commission decision is expected later this year. The company holds $678.3 million in cash, cash equivalents and marketable securities as of 30 June 2026, down from $728.9 million at year-end 2025. Second quarter net loss was $64.1 million compared to $17.4 million in the same period last year. NewAmsterdam plans an interim analysis of its PREVAIL cardiovascular outcomes trial in fourth quarter 2026, with results expected in first quarter 2027. Topline data from the RUBENS Phase 3 trial is anticipated by year-end 2026.
NewAmsterdam Pharma to host Investor Day on August 5, 2026. NAARDEN, The Netherlands and MIAMI, July 29, 2026 (GLOBE NEWSWIRE) - NewAmsterdam Pharma Company N.V. (Nasdaq: NAMS or "NewAmsterdam" or the "Company"), a late-stage, clinical biopharmaceutical company developing oral, non-statin medicines for patients at risk of cardiovascular disease ("CVD") with elevated low-density lipoprotein cholesterol ("LDL-C"), for whom existing therapies are not sufficiently effective or well-tolerated, today announced that it will host an Investor Day event for analysts and investors on August 5, 2026 beginning at 9:00 a.m. ET in New York City. Please join members of its management team, including: Michael Davidson, M.D., Chief Executive Officer; John Kastelein, M.D., Ph.D., FESC, Founder and Chief Scientific Officer; BJ Jones, Chief Commercial Officer; Ian Somaiya, Chief Financial Officer; and Matthew Philippe, Executive Vice President and Head of Investor Relations. A live webcast of the Investor Day event will be available, and those who intend to join virtually can pre-register for the webcast through the link here. The live webcast and supporting presentation materials will be available on the Events section of the Investor Relations page of the NewAmsterdam website at ir.newamsterdampharma.com at the time of the live event. An archived replay will be available on the NewAmsterdam website. Please note advanced registration is required for in-person attendance. About Obicetrapib Obicetrapib is a novel, oral, low-dose CETP inhibitor that NewAmsterdam is developing to overcome the limitations of current LDL-lowering treatments. In each of the Company's Phase 2 trials, ROSE2, TULIP, ROSE, and OCEAN, as well as the Company's Phase 3 BROOKLYN, BROADWAY and TANDEM trials, evaluating obicetrapib as monotherapy or combination therapy, the Company observed statistically significant LDL-lowering combined with a side effect profile similar to that of placebo. The Company commenced the Phase 3 PREVAIL cardiovascular outcomes trial in March 2022, which is designed to assess the potential of obicetrapib to reduce occurrences of MACE. The Company completed enrollment of PREVAIL in April 2024 and randomized over 9,500 patients. Commercialization rights of obicetrapib in Europe, either as a monotherapy or as part of a fixed-dose combination with ezetimibe, have been exclusively granted to the Menarini Group, an Italy-based, leading international pharmaceutical and diagnostics company. About NewAmsterdam NewAmsterdam Pharma (Nasdaq: NAMS) is a late-stage biopharmaceutical company whose mission is to improve patient care in populations with metabolic diseases where currently approved therapies have not been adequate or well tolerated. NewAmsterdam Pharma Company seek to fill a significant unmet need for a safe, well-tolerated and convenient therapy that lowers LDL-C while advancing innovation beyond a single marker to better address cardiovascular risk. In multiple phase 3 trials, NewAmsterdam is investigating obicetrapib, an oral, low-dose and once-daily CETP inhibitor, alone or as a fixed-dose combination with ezetimibe, as LDL-C lowering therapies to be used as an adjunct to statin therapy for patients at risk of CVD with elevated LDL-C, for whom existing therapies are not sufficiently effective or well tolerated. Media Contact Real Chemistry on behalf of NewAmsterdam Christian Edgington P: 1-513-310-6410 [email protected] Investor Contact Precision AQ on behalf of NewAmsterdam Austin Murtagh P: 1-212-698-8696 [email protected]